Related Experiment Videos
Inhibition of cytomegalovirus late antigens by phosphonoformate
Abstract:
Phosphonoformate (PFA) at a concentration of 500 muM and higher completely inhibited the replication of cytomegalovirus (CMV) in cell culture. 50% inhibition was obtained at a concentration of muM PFA. Early nuclear CMV antigens appeared uninhibited, but the formation of nuclear inclusion bodies, late cytoplasmic antigens, Fc-receptors and CPE were all inhibited by PFA. No visible cell toxicity was noted at the PFA concentrations and exposure times used.
Insights
Phosphonoformate (PFA) effectively inhibits cytomegalovirus (CMV) replication in cell cultures. This antiviral agent demonstrated significant efficacy without causing observable cell toxicity at tested concentrations.
Area of Science:
- Virology
- Cell Biology
- Pharmacology
Background:
- Human cytomegalovirus (CMV) is a significant human pathogen.
- Antiviral therapies are crucial for managing CMV infections.
Purpose of the Study:
- To investigate the antiviral activity of Phosphonoformate (PFA) against CMV replication.
- To determine the effective concentration of PFA for CMV inhibition.
- To assess the impact of PFA on viral antigen expression and cytopathic effects.
Main Methods:
- Cell culture experiments were conducted to assess CMV replication.
- Varying concentrations of PFA were applied to infected cell cultures.
- Viral antigen expression, inclusion body formation, Fc-receptor expression, and cytopathic effect (CPE) were evaluated.
Main Results:
- PFA completely inhibited CMV replication at concentrations of 500 muM and higher.
- A 50% inhibition of CMV replication was achieved at a specific muM concentration of PFA.
- Early nuclear CMV antigens were not inhibited, but late antigen formation, inclusion bodies, Fc-receptors, and CPE were suppressed.
- No significant cell toxicity was observed at the tested PFA concentrations and exposure durations.
Conclusions:
- Phosphonoformate exhibits potent antiviral activity against cytomegalovirus in vitro.
- PFA targets later stages of viral replication and assembly, sparing early antigen expression.
- PFA represents a potential therapeutic agent for CMV infections with a favorable safety profile in cell culture.